Table 2.
Demographics and clinical characteristics of MS patients.
| Patient ID | Sex | Age at Tx | Duration of MS prior to Tx (months) | Relapses in the 24M prior to Tx | No of MRIs with new/enlarging lesions in the 24M prior to Tx | Prior DMTs 1 | EDSS at baseline | Post‐Tx relapses/MRI activity | EDSS at 36M post‐Tx |
|---|---|---|---|---|---|---|---|---|---|
| MS001 | F | 52 | 188 | 0 | 2 | IFNβ1a, MTX, FIN, NTZ | 7 | N | 7.5 |
| MS002 | F | 22 | 62 | 3 | 3 | IFNβ1a, FIN | 3.5 | Relapse with right leg weakness at 13M | 2 |
| MS003 | M | 27 | 130 | 2 | 2 | IFNβ1a, NTZ | 4.5 | N | 6 |
| MS004 | F | 46 | 68 | 3 | 2 | IFNβ1a, GA, DMF | 4.5 | N | 4.5 |
| MS005 | F | 31 | 62 | 1 | 0 | GA, DMF | 4 | Single new non‐enhancing T2/FLAIR hyperintensity on MRI at 36M. No clinical correlate. | 4.5 |
| MS006 | M | 30 | 39 | 2 | 1 | IFNβ1a, FIN, NTZ | 4 | N | 4.5 |
| MS007 | M | 25 | 8 | 4 | 3 | FIN | 2 | N | 2 |
| MS008 | F | 35 | 47 | 2 | 2 | FIN, NTZ, plasma exchange, DMF | 3 | N | 0 |
| MS009 | F | 43 | 36 | 3 | 1 | FIN, NTZ | 5 | Relapse with left leg weakness at 23M | 3 |
| MS010 | M | 33 | 103 | 1 | 2 | IFNβ1a, GA, FIN, MTX | 4.5 | N | 1 |
| MS011 | M | 33 | 115 | 0 | 2 | IFNβ1a, FIN, NTZ, DMF | 7 | N | 8 |
| MS012 | F | 38 | 127 | 3 | 3 | IFNβ1a, FIN, NTZ | 4 | N | 0 |
| MS013 | F | 55 | 259 | 1 | 1 | IFNβ1a, GA, FIN, NTZ, DMF | 6.5 | Right upper limb weakness at 33M | 6.5 |
| MS014 | F | 38 | 142 | 2 | 2 | FIN, NTZ | 6 | N | 6.5 |
| MS015 | M | 31 | 25 | 3 | 4 | IFNβ1a, GA, DMF | 6.5 | N | 7 |
| MS016 | M | 29 | 99 | 2 | 2 | IFNβ1a, GA, DMF | 2 | N | 1 |
| MS017 | M | 28 | 73 | 2 | 1 | IFNβ1a, FIN | 2 | N | 2.5 |
| MS018 | F | 37 | 179 | 1 | 1 | IFNβ1a, GA, MTX, NTZ, DMF | 4 | N | 0 |
| MS019 | F | 37 | 17 | 5 | 6 | GA, NTZ | 6.5 | N | 3 |
| MS020 | F | 35 | 93 | 3 | 3 | IFNβ1a, FIN, NTZ | 6 | N | 3.5 |
| MS021 | M | 44 | 124 | 1 | 4 | IFNβ1a, GA, FIN, NTZ | 3.5 | Sensory disturbance involving right leg at 11M. | 4.5 |
| MS022 | M | 31 | 19 | 2 | 5 | FIN, NTZ | 2.5 | N | 2.5 |
DMF, Dimethyl fumarate; FIN, Fingolimod; GA, Glatiramer acetate; IFN, Interferon; MTX, Mitoxantrone; NTZ, Natalizumab; M, Months; N, No relapse/MRI activity; Tx, Transplant (AHSCT).
1
Pulse steroid use has not been included in this table.